1. Articles from Lydia Ramsey

    1-16 of 16
    1. UBiome's Independent Directors are Ditching the Healthcare Startup Following an FBI Raid

      UBiome's Independent Directors are Ditching the Healthcare Startup Following an FBI Raid
      • Microbiome-testing company uBiome's board now only has one independent director, following a raid of the company by the FBI in April.
      • In a letter to investors sent Tuesday, a special committee of uBiome's board of directors said that two board members, UCSF professor Joe DeRisi and early founder Witt Wisebram, have resigned...
      Read Full Article
    2. Bristol-Myers Squibb is Buying Celgene in a $74 Billion Deal

      Bristol-Myers Squibb is Buying Celgene in a $74 Billion Deal
      • Bristol-Myers Squibb has agreed to acquire Celgene, the drugmakers announced Thursday in a deal valued at $74 billion.
      • The deal will pay Celgene shareholders one BMS share and $50 cash for each Celgene share they own.
      • The deal combines a massive pharmaceutical company with a biotech giant, both of which have a big presence in cancer drug development...
      Read Full Article
    3. Cigna is Closing its $67 Billion Deal with Express Scripts, Creating a New Healthcare Giant

      Cigna is Closing its $67 Billion Deal with Express Scripts, Creating a New Healthcare Giant
      • Cigna is set to officially close its deal to acquire pharmacy benefits manager Express Scripts.
      • The deal was announced in March but took some time clearing regulatory hurdles from state insurance agencies as well as the Department of Justice.
      • The deal combines a health insurer and a company that helps negotiate lower prices for prescription drugs in the form of rebates on behalf of health plans.

      Cigna is about to close on its deal to acquire healthcare giant Express Scripts...

      Read Full Article
    4. Merck's Board Just Changed the Rules to Keep its CEO on Board After he Turns 65

      Merck's Board Just Changed the Rules to Keep its CEO on Board After he Turns 65
      • Merck CEO Kenneth Frazier plans to stay on in his role as CEO past December 2019, when he turns 65.
      • The pharma giant's board of directors had to overturn a mandatory CEO retirement policy in order for Frazier to stay on.
      • Frazier, who became CEO in 2011, gained national attention after he was the first to depart President Donald Trump now-disbanded manufacturing council...
      Read Full Article
      Mentions: Harvard retire Merck
    5. Celgene is Buying Cancer Drugmaker Juno Therapeutics for $9 Billion

      Celgene is Buying Cancer Drugmaker Juno Therapeutics for $9 Billion
      • Celgene is acquiring Juno Therapeutics, a company developing personalized cancer treatments in a deal worth $9 billion.
      • It's the second deal in 2018 for the biotech giant, which has been under pressure from investors.
      • The highly personalized treatments Juno makes, called CAR T-cell therapy, are at the beginning of what some are calling "a big new field of medicine...
      Read Full Article
    6. The first female big pharma CEO had the perfect response to a question about women in leadership

      The first female big pharma CEO had the perfect response to a question about women in leadership

      GlaxoSmithKline CEO Emma Walmsley made history in 2017, when she became the first woman to head up a major pharmaceutical company. 

      In her first company presentation at an industry conference as the CEO of GSK, Walmsley was asked about female leadership in the pharmaceutical industry. She responded not by talking about gender, but by running through how she thinks about her responsibilities as CEO. 

       

      Read Full Article
    7. The CEO of Aetna is Going to Make a Huge Amount of Money if the $69 Billion Deal With CVS Closes

      The CEO of Aetna is Going to Make a Huge Amount of Money if the $69 Billion Deal With CVS Closes
      • Aetna CEO Mark Bertolini stands to make a lot from Aetna's $69 billion deal with CVS Health once it closes.
      • Bertolini could make as much as $85 million in exit pay from the deal closing, The Wall Street Journal reports.
      • Combined with the other stock and rights Bertolini has in Aetna and based on the $207 share price of the deal, Bertolini's payout will be $500 million by the time the deal closes, The Journal reported...
      Read Full Article
    8. CVS and Aetna Used One Word that Should Make Employees Nervous

      CVS and Aetna Used One Word that Should Make Employees Nervous
      • CVS Health is buying Aetna for $69 billion ($145 a share and 0.8378 CVS shares per Aetna share).
      • The merger could reshape the American healthcare system as we know it.
      • CVS and Aetna said that the deal will come with some synergies.

      In the largest deal of 2017, CVS Health is buying Aetna, the third largest US insurer, for $69 billion. Aetna stockholders will be paid $145 a share in cash and 0.8378 CVS shares per Aetna share...

      Read Full Article
      Mentions: CFO Merger
    9. GE Executive John Flannery is About to become CEO — Here's How he Built his Career at the Company

      GE Executive John Flannery is About to become CEO — Here's How he Built his Career at the Company

      John Flannery, who has run GE's Healthcare business just got tapped to become the company's CEO and chairman, replacing Jeff Immelt.Flannery, 55, is a 30-year veteran of the company he will run. He worked for two decades in financial services before running GE's business in India and eventually leading GE Healthcare, an $18 billion business, for the last three years...

      Read Full Article
      Mentions: MDC Partners
    10. The Chairman of the Company Behind the EpiPen Reportedly Flipped Everyone off when they asked about Drug Pricing

      The Chairman of the Company Behind the EpiPen Reportedly Flipped Everyone off when they asked about Drug Pricing

      A number of drug companies have been criticized for the increased prices of their medication over the past few years.

      Mylan, the company that makes the emergency allergy medication EpiPen, was one of them.

      According to a new report by The New York Times, the outrage had been a long time coming — Mylan employees were concerned about the price increases as early as 2014.

      At one point, the employees brought it up with Mylan's chairman Robert Coury...

      Read Full Article
    11. The Chairman of the Company Behind the EpiPen Made $98 Million in 2016

      The Chairman of the Company Behind the EpiPen Made $98 Million in 2016

      Mylan's chairman Robert Coury made roughly $98 million in 2016, a year in which the company faced criticism for the price of the EpiPen and the stock fell almost 30%, according to company filings.

      On top of that, The Wall Street Journal reported, Coury made $66.3 million in other payments, including retirement benefits, bringing the amount he made in 2016 to $164 million...

      Read Full Article
    12. Theranos Just Settled 2 Lawsuits with one of its Biggest Investors

      Theranos Just Settled 2 Lawsuits with one of its Biggest Investors

      Theranos has settled its lawsuits with a hedge fund that invested $96.1 million in the company.

      Partner Fund Management originally sued Theranos in October 2016, alleging the company had "engaged in securities fraud and other violations."

      And in April, court filings reported by The Wall Street Journal alleged that Theranos used a shell company to purchase commercially available lab equipment and faked blood tests in presentations with prospective investors and business partners...

      Read Full Article
    13. What We Know About the Former Valeant Employee who Just Got Arrested on Fraud Charges

      What We Know About the Former Valeant Employee who Just Got Arrested on Fraud Charges

      Prosecutors in New York have charged two executives over a kickback scheme meant to inflate the value of a specialty pharmacy before it was sold to Valeant Pharmaceuticals.  This isn't over yet, but the charges filed so far are putting the focus on a man who worked for both Valeant and Philidor, the specialty pharmacy that was selling Valeant's products directly to patients...

      Read Full Article
      Mentions: MDC Partners
    14. These 3 Charts Show How Drastically Valeant has Changed over the past year (VRX)

      These 3 Charts Show How Drastically Valeant has Changed over the past year (VRX)

      Valeant reported mixed earnings Tuesday morning, and the stock is up 13%.

      "I am continuously encouraged by the commitment of our employees who work hard daily, rebuilding our relationships with prescribers, patients and payors, and regaining the trust of our debt holders and shareholders," Valeant CEO Joseph Papa said in a release...

      Read Full Article
    15. Hated Pharma CEO Martin Shkreli is the Villain We Need

      Hated Pharma CEO Martin Shkreli is the Villain We Need

      Pharma CEO Martin Shkreli is easy to hate, but that doesn't mean he's wrong. Shkreli is infamous for jacking up the price of a 62-year-old drug by 5,000%, and then defending the move as the innevitable product of capitalism.  His company, Turing Pharmaceuticals, is small, and the drug, Daraprim, is rarely used. Nevertheless, the move grabbed national attention...

      Read Full Article
      Mentions: MDC Partners
    16. Controversial Health Startup Theranos Has a Board of Directors That's Anything But Medical Experts

      Controversial Health Startup Theranos Has a Board of Directors That's Anything But Medical Experts

      A Wall Street Journal report published Thursday alleged that Theranos, the $10-billion health startup whose blood tests can allegedly be done with a single drop, has a few problems.  In a follow-up article published later Thursday evening, the Journal reported that the company had stopped using its signature finger-prick blood test on all but one of its more than 240 blood tests...

      Read Full Article
    1-16 of 16
  1. Categories

    1. BoardProspects Features:

      BoardBlogs, BoardKnowledge, BoardMoves, BoardNews, BoardProspects Announcements, BoardProspects CEO, CEO Blog, In the News, Partner Publications, Sponsored Content
  2. Topics in the News

    1. (13 articles) MDC Partners
    2. (7 articles) Board of Directors
    3. (4 articles) acquisition
    4. (3 articles) Investors
    5. (2 articles) Merck
    6. (2 articles) Mylan
    7. (2 articles) Management
    8. (2 articles) Epipen
    9. (1 articles) Carl Icahn
    10. (1 articles) California
    11. (1 articles) Marcos Lutz
    12. (1 articles) Steven Strom
    13. (1 articles) Schmitt Industries
    14. (1 articles) Greyhound
    15. (1 articles) Bayer
    16. (1 articles) Elliott Management
    17. (1 articles) Activist Investors
  3. Popular Articles

  4. Picture Gallery

    Controversial Health Startup Theranos Has a Board of Directors That's Anything But Medical Experts Hated Pharma CEO Martin Shkreli is the Villain We Need These 3 Charts Show How Drastically Valeant has Changed over the past year (VRX) What We Know About the Former Valeant Employee who Just Got Arrested on Fraud Charges Theranos Just Settled 2 Lawsuits with one of its Biggest Investors The Chairman of the Company Behind the EpiPen Made $98 Million in 2016 The Chairman of the Company Behind the EpiPen Reportedly Flipped Everyone off when they asked about Drug Pricing GE Executive John Flannery is About to become CEO — Here's How he Built his Career at the Company CVS and Aetna Used One Word that Should Make Employees Nervous The first female big pharma CEO had the perfect response to a question about women in leadership Bayer Seeks Glyphosate Litigation Advice as Elliott Reveals Stake Schmitt Industries Appoints Steven Strom to Its Board